Thu, Nov 27, 2014, 12:55 PM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

  • lottopol.geo lottopol.geo Oct 17, 2004 8:39 PM Flag

    Concerns regarding SNY'Acomplia Safety

    http://richandthin.bravehost.com/Archive10172004.html

    The highly anticipated obesity drug from Sanofi-Synthelabo SA SNY: (NYSE ADR) Acomplia (Rimonabant) is a small molecule antagonist of the CB-1 receptor. The "CB" in the receptor name stands for "cannabinoid", and the drug blocks the same receptor whose stimulation causes the well-known food cravings brought on by marijuana. Blockade of this receptor not only seems to affect appetite, but also seems to help with cravings for nicotine.

    We had added SNY to our model portfolio based on promising Phase III results that demonstrated Acomplia's efficacy against obesity and nicotine cravings. However, recent disturbing news raising questions about side effect of Acomplia have led us to remove our buy recommendation for SNY.

    Most worrisome is a patient suddenly came down with multiple sclerosis after having been a subject in a rimonabant trial. There's some evidence that CB-1 has a neuroprotective effect under normal conditions. So blocking its actions might conceivably expose neurons to damage.

    The MS concern comes on top of a report that Vanderbilt University researchers are expressing concern that the diet drug Acomplia (rimonabant) may potentially increase the risk of ectopic pregnancies in young women, according to a report in the October issue of the journal Nature Medicine.

    Ectopic pregnancy occurs when a fertilized egg implants in tissue outside of the uterus, and the placenta and fetus begin to develop there. The most common site is within a fallopian tube. The Vanderbilt researchers, in a study of the CB1 receptor which is targeted by Acomplia, found that in pregnant mice that lacked the gene for the receptor, or in which the receptor was blocked, the embryo failed to go through the oviduct � the tube leading from the ovaries to the uterus.

    It is not known whether drugs that block the CB1 receptor can cause ectopic pregnancy in humans. According to the U.S. Centers for Disease Control and Prevention, about 100,000 ectopic pregnancies occur in the United States each year (out of more than 6 million total pregnancies) and account for about 9 percent of all pregnancy-related deaths in the country.

    Even though Acomplia has been tested on more than 13,000 people in Phase III trials, if the odds are that 1 in 13,000 that it causes MS, that would probably doom Acomplia. That there is a proposed causation by which Acomplia's action on the nervous system leads to MS and an actual case of MS in an Acomplia trial voulf preclude FDA approval.

    We are contuing our buy recomendations on Lexicon: Genetics (Nasdaq: LEXG) .Metabolic Pharmaceuticals (MBP:AU), Regeneron Pharmaceuticals Inc.(REGN) and CuraGen Corp. (CRGN).

    The shares of Metabolic Pharmaceuticals Ltd. an Australian company also trade over the counter in the USA with the symbol MBLPF. They have risen to new highs on anticipation of the results of a Phase IIb study ofMetabolic�s candidate obesity drug, AOD9604, invented at Monash University.It acts specifically on the body�s fat cells to enhance the breakdown of stored fats and inhibit the synthesis of new fat. This result is biochemically similar to the slimming effects of physical exercise.

    AOD9604 has proven to be effective in reducing obesity in laboratory animals through once daily oral administration, with no effect on food intake. The drug is modelled on the active fat reducing portion of the human Growth Hormone (hGH) molecule. hGH occurs naturally in the body and is involved in promoting growth. In addition it has pronounced effects on body fat. Scientists at Monash University have shown that, when dosed to animals, AOD9604 has the fat-reducing effects of the intact growth hormone without its other unwanted effects having been observed.

    A double-blind Phase IIb study on 300 patients in Australian hospital has been compl

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • SNY is a 60. stock!

    • This news release reads a lot like the paid-for-endorsements I receive in the mail, usually touting "undiscovered" gold mines or "magical" technical devices or, lately, "new" sources of oil.
      I would like to know the connection between "richandthin" and Metabolic Pharmaceuticals Ltd. before I put any credence in it.

    • NONSENSE from Rich-and-Thin website.

      <<Most worrisome is that a patient suddenly came down with multiple sclerosis after having been a subject in a rimonabant trial. There's some evidence that CB-1 has a neuroprotective effect under normal conditions. So blocking its actions might conceivably expose neurons to damage.>>

      1 case in 13,000 does not even raise concerns. To attribute causality to one random event is sheer scientific nonsense. Chicken Little had better go back to school, it knows nothing about science. Their reasoning is pretty thin.

      • 2 Replies to joepalookaboggs
      • NONSENSE from Rich-and-Thin website.

        <<Most worrisome is that a patient suddenly came down with multiple sclerosis after having been a subject in a rimonabant trial. There's some evidence that CB-1 has a neuroprotective effect under normal conditions. So blocking its actions might conceivably expose neurons to damage.>>

        1 case in 13,000 does not even raise concerns. To attribute causality to one random event is sheer scientific nonsense. Chicken Little had better go back to school, it knows nothing about science. Their reasoning is pretty thin.
        >>>>>>>>>>>>>>>>>>

        Rimonabant: An association with neurological disease and fertility problems.
        A recent case report of multiple sclerosis in a subject from the rimonabant (SR141716A) weight loss trial has caused concern about possible adverse central nervous system (CNS) effects resulting from long term use of this drug. When cannabinoids are stimulated either by marijuana or cannabinoid agonists, appetite, especially for sweet and palatable foods, is increased. Rimonabant, a cannabinoid-1 (CB1) receptor antagonist, reverses these effects, and subjects taking this drug lose weight. However, cannabinoids have many other functions besides stimulating appetite. CB1 receptors are highly concentrated in areas of the brain responsible for motor control, short-term memory, and emotions. Animal research has found that CB1 receptor deficiency can lead to colon and CNS inflammation, deficits in brain development, memory, coordination, vasoregulation, thermoregulation, and pain regulation.

        The case, reported in the June issue of the journal Multiple Sclerosis, was a 48-year old female patient, who had no previous history of neurological symptoms. She developed MS after receiving 6 months of rimonabant 5 mg in a clinical trial. Her MRI showed physical signs of MS: a spinal cord lesion, consistent with demyelination, as well as three cerebral white matter lesions. She also had changes in her cerebral spinal fluid consistent with the disease. Upon discontinuing the medication, the patient recovered to near normal, and one year later she has no new neurological symptoms. However, since that time she has developed a new periventricular white matter lesion, and fills the criteria for having MS.

        The patient's physicians believe that rimonabant contributed to the development of her disease, and they suggest that individuals taking rimonabant be carefully monitored for neurological symptoms, and possibly followed-up with MRI studies of the brain and spinal cord.

      • To attribute causality to one random event is sheer scientific nonsense. Their reasoning is pretty thin. Removing a stock from a "recommended portfolio" on the basis of this "evidence" is a "just-in-case" response. People even die during clinical trials, from causes unrelated to the drug. You just mention this as an event, there is not even a good case for linking it to the drug.

 
SNY
48.09+0.44(+0.92%)Nov 26 4:02 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.